Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Rhynchophylline** is a natural tetracyclic oxindole alkaloid derived primarily from *Uncaria rhynchophylla*, a traditional medicinal plant. It is recognized for its neuroprotective, anti-inflammatory, antihypertensive, antiarrhythmic, anti-addictive, anticonvulsant, and sedative effects. Mechanistically, rhynchophylline acts as a modulator of neurotransmitters, suppressor of calcium and potassium channels, and has demonstrated inhibition of ephrin type A receptor 4 (EphA4) tyrosine kinase and suppression of inflammation via inhibition of MAPK/NF-κB signaling. It has been shown to reduce neuronal apoptosis and inflammation, prevent neurotoxicity in PD and AD models, and modulate several metabolic and signaling pathways relevant to neurodegenerative and cardiovascular diseases[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhynchophylline.